Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06790602 | Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | PHASE2 | RECRUITING | 43 | — | — | Apr 1, 2026 | Dec 1, 2029 | Apr 9, 2026 | 1 | United States |
To evaluate the overall survival of participants with metastatic pancreatic adenocarcinoma harboring SWI/SNF alterations treated with cemiplimab in combination with gemcitabine as a second-line treatment.
| Arm | Type | Description |
|---|---|---|
| Cemiplimab Plus Gemcitabine | EXPERIMENTAL | Combination therapy of cemiplimab plus gemcitabine. Cemiplimab will be supplied as 350 mg vials for intravenous administration at 3 mg/Kg every 2 weeks. Gemcitabine will be administered intravenously per standard of care at 1000mg/m\^2 on days 1, 8, 15 of every 28-day cycle. Cemiplimab plus gemcitabine will be administered until disease progression or other reasons that warrant discontinuation. |
| Name | Type | Description |
|---|---|---|
| Cemiplimab Plus Gemcitabine | DRUG | Cemiplimab Plus Gemcitabine |
Inclusion Criteria: 1. At least 18 years of age. 2. Ability to understand the nature of this study, comply with study and follow-up procedures, and give written informed consent. 3. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma. Primary tumor can be intact or post-resec...